Comparing the Risk of Adverse Pregnancy Outcomes of Chinese Patients with Polycystic Ovary Syndrome with and without Antiandrogenic Pretreatment
March 2018
in “
Fertility and Sterility
”
TLDR Women with PCOS who had antiandrogenic treatment before pregnancy had fewer complications than those without treatment.
In a 2018 retrospective study involving Chinese women, it was found that those with polycystic ovary syndrome (PCOS) who did not receive antiandrogenic pretreatment had a higher risk of adverse pregnancy outcomes such as gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH), and preterm delivery (PD) compared to healthy women and PCOS patients who received 3 months of ethinylestradiol/cyproterone acetate (EE/CPA) pretreatment. The study included 6,000 healthy women, 448 PCOS patients without pretreatment, and 222 PCOS patients with pretreatment. The results indicated that EE/CPA pretreatment could reduce the risk of these adverse outcomes, suggesting its potential as a beneficial clinical practice for PCOS patients planning to conceive. However, the study's retrospective nature and potential lack of generalizability to obese women with PCOS were noted as limitations, and further research was recommended.
